Graf Anneke, McAuley Sybil A, Sims Catriona, Ulloa Johanna, Jenkins Alicia J, Voskanyan Gayane, O'Neal David N
1 Department of Endocrinology & Diabetes, St Vincent's Hospital Melbourne, Melbourne, Australia.
2 Department of Medicine, University of Melbourne, Melbourne, Australia.
J Diabetes Sci Technol. 2017 Mar;11(2):308-314. doi: 10.1177/1932296816682762. Epub 2016 Dec 13.
Advances in insulin pump and continuous glucose monitoring technology have primarily focused on optimizing glycemic control for people with type 1 diabetes. There remains a need to identify ways to minimize the physical burden of this technology. A unified platform with closely positioned or colocalized interstitial fluid glucose sensing and hormone delivery components is a potential solution. Present challenges to combining these components are interference of glucose sensing from proximate insulin delivery and the large discrepancy between the life span of current insulin infusion sets and glucose sensors. Addressing these concerns is of importance given that the future physical burden of this technology is likely to be even greater with the ongoing development of the artificial pancreas, potentially incorporating multiple hormone delivery, glucose sensing redundancy, and sensing of other clinically relevant nonglucose biochemical inputs.
胰岛素泵和持续血糖监测技术的进展主要集中在优化1型糖尿病患者的血糖控制。仍有必要找出方法来减轻这项技术带来的身体负担。一个将间质液葡萄糖传感和激素输送组件紧密定位或共定位的统一平台是一个潜在的解决方案。目前将这些组件结合起来面临的挑战是，临近的胰岛素输送会干扰葡萄糖传感，以及当前胰岛素输注装置和葡萄糖传感器的使用寿命存在巨大差异。鉴于随着人工胰腺的不断发展，这项技术未来的身体负担可能会更大，因为人工胰腺可能会整合多种激素输送、葡萄糖传感冗余以及对其他临床相关非葡萄糖生化输入的传感，所以解决这些问题至关重要。
